BeyondSpring is trading 6.3% up at $1.77 in pre-market, extending a modest rebound following its recent removal from the Russell 3000E Growth Benchmark.

  • The company announced multiple executive leadership changes effective July 1, 2026.
  • Updates were provided for the Plinabulin clinical program in NSCLC, which remains a core component of the company's broader fundamental outlook.